You have 9 free searches left this month | to do more

elotuzumab

Elotuzumab is a drug used to treat Multiple Myeloma, Plasma Cell Myeloma, AML, Adult, and other conditions. Elotuzumab is being actively studied in 22 studies and prior, has been studied in 9.

Top SponsorsTop SitesTop Investigators
Bristol-Myers SquibbLocal InstitutionJacob Laubach
Dana-Farber Cancer InstituteMassachusetts General HospitalAndrew Yee, MD
University of ArkansasColorado Blood Cancer InstituteBinod Dhakal
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Active, not recruiting
  • IgG4 Related Disease
  • IgG4-RD
  • elotuzumab
  • +6 more
  • Atlanta, Georgia
  • +2 more
2022-03-07
Mar 7, 2022
Y
Enrolling by invitation
  • Multiple Myeloma
  • Elotuzumab
  • Belantamab mafodotin
  • New Haven, Connecticut
    Yale New Haven Hospital
2022-02-28
Feb 28, 2022
N
Withdrawn
  • Multiple Myeloma
  • (no location specified)
2021-08-18
Aug 18, 2021
H
Active, not recruiting
  • Multiple Myeloma
  • Elotuzumab
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2021-11-15
Nov 15, 2021
M
Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • Plasma Cell Myeloma
  • Elotuzumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-02
Feb 2, 2022
M
Recruiting
  • Multiple Myeloma
  • Isatuximab (for run-in portion)
  • +4 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
2022-02-18
Feb 18, 2022
D
Active, not recruiting
  • Multiple Myeloma
  • Atlanta, Georgia
  • +6 more
2021-12-17
Dec 17, 2021
M
Active, not recruiting
  • Multiple Myeloma
  • Elotuzumab
  • +3 more
  • Boston, Massachusetts
  • +5 more
2021-10-28
Oct 28, 2021
B
No longer available
  • Multiple Myeloma
  • Elotuzumab
  • +2 more
  • Nagoya-shi, Aichi, Japan
  • +3 more
2021-11-17
Nov 17, 2021
M
Active, not recruiting
  • Multiple Myeloma
  • Elotuzumab
  • Charlotte, North Carolina
    Levine Cancer Institute
2022-01-21
Jan 21, 2022
B
Terminated
  • Newly Diagnosed, Previously Untreated Multiple Myeloma
  • San Francisco, California
  • +13 more
2021-06-29
Jun 29, 2021
O
Terminated
  • Multiple Myeloma
  • Elotuzumab
  • +3 more
  • Encinitas, California
  • +5 more
2022-03-15
Mar 15, 2022
D
Active, not recruiting
  • Smoldering Myeloma
  • Smoldering Multiple Myeloma
  • Elotuzumab
  • +2 more
  • Denver, Colorado
  • +8 more
2021-11-01
Nov 1, 2021
U
Withdrawn
  • Multiple Myeloma
  • Elotuzumab
  • +4 more
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences
2020-07-08
Jul 8, 2020
B
Active, not recruiting
  • Multiple Myeloma
  • Elotuzumab
  • +5 more
  • Tucson, Arizona
  • +37 more
2022-01-14
Jan 14, 2022
W
Active, not recruiting
  • Newly Diagnosed Multiple Myeloma
  • Elotuzumab
  • +4 more
  • Krems, Lower Austria, Austria
  • +55 more
2022-01-04
Jan 4, 2022
B
Active, not recruiting
  • Recurrent Primary Amyloidosis
  • Duarte, California
  • +4 more
2021-03-10
Mar 10, 2021
W
Active, not recruiting
  • Multiple Myeloma in Relapse
  • Elotuzumab
  • +2 more
  • Denver, Colorado
  • +2 more
2021-10-14
Oct 14, 2021
U
Active, not recruiting
  • Multiple Myeloma
  • Elotuzumab
  • +3 more
  • Chicago, Illinois
  • +2 more
2021-11-12
Nov 12, 2021
S
Completed
  • Multiple Myeloma
  • elotuzumab
  • +3 more
  • Denver, Colorado
  • +5 more
2021-10-25
Oct 25, 2021
M
Suspended
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
2021-10-18
Oct 18, 2021
M
Active, not recruiting
  • Plasma Cell Leukemia
  • Plasma Cell Myeloma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-09
Nov 9, 2021
A
Withdrawn
  • Multiple Myeloma
  • Elotuzumab
  • Paris, France
    Hématologie et thérapie cellulaire, Hôpital Saint Antoine
2019-07-15
Jul 15, 2019